February 2018

LONDON and CARLSBAD, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted orphan drug designation for cannabidiol (CBD) for the […]

by

GW Pharma’s cannabidiol (CBD) has been granted orphan drug designation by European regulators for the treatment of tuberous sclerosis (TS). TS is a potentially life-threatening, genetic disease that causes benign tumors to grow in the brain and on other vital organs. Up to 80 to 90 percent of individuals with TS will develop epilepsy during […]

by

The Hydroponics Company (ASX: THC) has been given the green light to import medicinal cannabis products from its European partner Endoca after locking in a distribution deal last November. The company also today announced it will be supporting an upcoming clinical trial for the treatment of Tourette’s Syndrome, via its recent collaboration with BOL Pharma. […]

by

This profile is part of an investor education campaign. The profile provides detailed information which was sourced and approved by Kalytera Therapeutics in order to help investors make better investment decisions. The Company’s support of Investing News Network ensures we can continue to bring you unbiased, independent news and information. Resource Investing News Featured Stock Overview Kalytera Therapeutics, […]

by

LONDON and CARLSBAD, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted orphan drug designation for cannabidiol (CBD) for the […]

by

SAN DIEGO, CA / ACCESSWIRE / February 26, 2018 / Emerald Health Pharmaceuticals Inc. (EHP), which is developing medicines based on cannabinoid science, today announced that it has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its drug candidate, EHP-102, a patented cannabigerol (CBG) derivative, for the treatment of […]

by

Market News Emerald Health Pharmaceuticals, a division of Emerald Health Therapeutics (TSXV:EMH), announced that it has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its drug candidate, EHP-102 treating Huntington’s disease. As quoted in the press release: ”Having secured orphan designation for our lead product, EHP-101, a cannabidiol (CBD) derivative, for systemic […]

by

Interest in cannabidiol (CBD) has taken off over the past five years since Sanjay Gupta, the Chief Medical Correspondent at CNN, highlighted its promise in the documentary Weed. GW Pharma (NASDAQ: GWPH) has submitted a New Drug Application for its CBD-based Epidiolex with the FDA, and it is probable that the agency will approve it […]

by

SAN DIEGO, CA / ACCESSWIRE / February 26, 2018 / Emerald Health Pharmaceuticals Inc. (EHP), which is developing medicines based on cannabinoid science, today announced that it has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its drug candidate, EHP-102, a patented cannabigerol (CBG) derivative, for the treatment of […]

by

Medical cannabis from Minnesota Medical Solutions Medical cannabis from Minnesota Medical Solutions (KMSP) – The Minnesota Department of Health has added autism spectrum disorders and obstructive sleep apnea to the list of conditions that qualify for medical cannabis.  MDH used a formal petitioning process used to solicit public input on potential qualifying conditions for medical […]

by

According to Hexa Research, the U.S. medical cannabis market was valued at USD 5.44 billion in 2016 and is expected to be valued at USD 19.48 billion by 2024. The expected growth is driven by the growing acceptance of medical advantages linked with cannabis, particularly for patients with cancer, diabetes and chronic pain. Symptoms and […]

by

by John Sidline , Columnist, December 19, 2017 In 2001, the song “Boom” dropped. This hard rock anthem was featured so frequently during football kickoffs that by 2012 it was simultaneously anointed one of the “10 Best Songs for the NFL Season” and one… read more at: https://www.mediapost.com/publications/article/311840/the-cannabis-industrys-insular-market-trap.html

by